Agency Information Collection Activities: Submission for OMB Review; Comment Request, 27756-27757 [2020-09961]
Download as PDF
<![CDATA[
27756
Federal Register / Vol. 85, No. 91 / Monday, May 11, 2020 / Notices
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, RFP 75N93019R00024,
‘‘Chemistry Center for Combating AntibioticResistant Bacteria (CC4CARB)’’.
Date: June 9–10, 2020.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, 3G13, Rockville,
MD 20892 (Telephone Conference Call).
Contact Person: Brenda Lange-Gustafson,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, 3G13,
Rockville, MD 20852, 240–669–5047,
bgustafson@niaid.nih.gov,
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 5, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09977 Filed 5–8–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
VerDate Sep<11>2014
17:05 May 08, 2020
Jkt 250001
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, HIV/AIDS Clinical Trial
Units.
Date: June 5–8, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Cynthia Louise De La
Fuente, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3G31, Rockville, MD 20852, 240–669–2740,
delafuentecl@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 5, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09979 Filed 5–8–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, email or call the SAMHSA
Reports Clearance Officer at
carlos.graham@samhsa.hhs.gov or (240)
276–0361.
Proposed Project: Program Evaluation
for Prevention Contract (PEPC)—
Strategic Prevention Framework for
Prescription Drugs (SPF–Rx) Evaluation
(OMB No. 0930–0377)—Revision
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA) Center for Behavioral Health
Statistics and Quality (CBHSQ) aims to
complete a cross-site evaluation of
SAMHSA’s Strategic Prevention
Framework for Prescription Drugs (SPF–
Rx). SPF–Rx is designed to address
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
nonmedical use of prescription drugs as
well as opioid overdoses by raising
awareness about the dangers of sharing
medications and by working with
pharmaceutical and medical
communities on the risks of
overprescribing. The SPF–Rx program
aims to promote collaboration between
states/tribes and pharmaceutical and
medical communities to understand the
risks of overprescribing to youth ages
12–17 and adults 18 years of age and
older. The program also aims to enhance
capacity for, and access to, Prescription
Drug Monitoring Program (PDMP) data
for prevention purposes. This request
for data collection includes a revision
from previously approved OMB
instruments.
The SPF–Rx program’s indicators of
success are reductions in opioid
overdoses, reductions in prescription
drug misuse, and improved use of
PDMP data. Data collected through the
tools described in this statement will be
used for the national cross-site
evaluation of SAMHSA’s SPF–Rx
program. This package covers continued
data collection through 2023. The PEPC
team will systematically collect and
maintain an Annual Implementation
Instrument (AII) and Grantee and
Community Level Outcomes data
modules submitted by SPF–Rx grantees
through the online Data Management
System (DMS).
SAMHSA is requesting approval for
data collection for the SPF–Rx cross-site
evaluation with the following
instruments:
• Annual Implementation Instrument
(AII)—The AII is a survey instrument
collected yearly to monitor state, tribal
entity, and community-level
performance, and to evaluate the
effectiveness of the SPF–Rx program.
This tool is completed by grantees and
subrecipient community project
directors, and provides process data
related to funding use and effectiveness,
organizational capacity, collaboration
with community partners, data
infrastructure, planned intervention
targets, intervention implementation,
evaluation, contextual factors, training
and technical assistance (T/TA) needs,
and sustainability.
• Grantee-and Community-Level
Outcomes Modules—These modules
collect data on key SPF–Rx program
outcomes, including opioid prescribing
patterns and provider use of PDMP.
Grantees will provide outcomes data at
the grantee level for their state, tribal
area, or jurisdiction, as well as at the
community level for each of their
subrecipient communities.
• Grantee-Level Interview—This
qualitative interview will be
E:\FR\FM\11MYN1.SGM
11MYN1
27757
Federal Register / Vol. 85, No. 91 / Monday, May 11, 2020 / Notices
administered at the end of the
evaluation to obtain information from
the grantee project directors on their
programs, staffing, populations of focus,
infrastructure, capacity, lessons learned,
and collaboration.
ANNUALIZED DATA COLLECTION BURDEN BY YEAR
Number of
respondents
Instrument
Total number
of responses
Hours per
response
Total burden
hours
Annual implementation instrument ......................................
Grantee-Level Outcomes Module ........................................
Community-Level Outcomes Module ...................................
Grantee-Level Interview .......................................................
148
25
25
25
1
1
4.92
1
148
25
123
25
4
2.5
1.25
1.5
592
62.5
153.75
37.5
FY2021 .........................................................................
Annual Implementation Instrument ......................................
Grantee-Level Outcomes Module ........................................
Community-Level Outcomes Module ...................................
223
148
25
25
........................
1
1
4.92
321
148
25
123
........................
4
2.5
1.25
845.75
592
62.5
154.75
FY2022 .........................................................................
Annual Implementation Instrument ......................................
Grantee-Level Outcomes Module ........................................
Community-Level Outcomes Module ...................................
198
39
7
7
........................
1
1
4.57
296
39
7
32
........................
4
2.5
1.25
808.25
156
17.5
40
FY2023 .........................................................................
53
........................
78
........................
213.5
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Carlos Graham,
Social Science Analyst.
[FR Doc. 2020–09961 Filed 5–8–20; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID FEMA–2008–0010]
Board of Visitors for the National Fire
Academy; Meeting
Federal Emergency
Management Agency, DHS.
ACTION: Committee Management; Notice
of Open Federal Advisory Committee
Meeting.
AGENCY:
The Board of Visitors for the
National Fire Academy (Board) will
meet via teleconference on Tuesday,
June 9, 2020. The meeting will be open
to the public.
DATES: The meeting will take place on
Tuesday, June 9, 2020, 1:30 to 3:30 p.m.
EDT. Please note that the meeting may
close early if the Board has completed
its business.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Responses
per
respondent
VerDate Sep<11>2014
17:05 May 08, 2020
Jkt 250001
Members of the public who
wish to participate in the teleconference
should contact Deborah Gartrell-Kemp
as listed in the FOR FURTHER
INFORMATION CONTACT section by close of
business June 1, 2020, to obtain the callin number and access code for the June
9 teleconference meeting. For more
information on services for individuals
with disabilities or to request special
assistance, contact Deborah GartrellKemp as soon as possible.
To facilitate public participation, we
are inviting public comment on the
issues to be considered by the Board as
listed in the SUPPLEMENTARY
INFORMATION section. Participants
seeking to have their comments
considered during the meeting should
submit them in advance or during the
public comment segment. Comments
submitted up to 30 days after the
meeting will be included in the public
record and may be considered at the
next meeting. Comments submitted in
advance must be identified by Docket ID
FEMA–2008–0010 and may be
submitted by one of the following
methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail/Hand Delivery: Deborah
Gartrell-Kemp, 16825 South Seton
Avenue, Emmitsburg, Maryland 21727,
post-marked no later than May 23, 2020,
for consideration at the June 9, 2020,
meeting.
Instructions: All submissions received
must include the words ‘‘Federal
Emergency Management Agency’’ and
the Docket ID for this action. Comments
received will be posted without
alteration at https://www.regulations.gov,
ADDRESSES:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
including any personal information
provided.
Docket: For access to the docket to
read background documents or
comments received by the National Fire
Academy Board of Visitors, go to https://
www.regulations.gov, click on
‘‘Advanced Search,’’ then enter
‘‘FEMA–2008–0010’’ in the ‘‘By Docket
ID’’ box, then select ‘‘FEMA’’ under ‘‘By
Agency,’’ and then click ‘‘Search.’’
FOR FURTHER INFORMATION CONTACT:
Alternate Designated Federal Officer:
Kirby E. Kiefer, telephone (301) 447–
1117, email Kirby.Kiefer@fema.dhs.gov.
Logistical Information: Deborah
Gartrell-Kemp, telephone (301) 447–
7230, email Deborah.GartrellKemp@
fema.dhs.gov.
The Board
will meet via teleconference on
Tuesday, June 9, 2020. The meeting will
be open to the public. Notice of this
meeting is given under the Federal
Advisory Committee Act, 5 U.S.C.
Appendix.
SUPPLEMENTARY INFORMATION:
Purpose of the Board
The purpose of the Board is to review
annually the programs of the National
Fire Academy (Academy) and advise the
Administrator of the Federal Emergency
Management Agency (FEMA), through
the United States Fire Administrator, on
the operation of the Academy and any
improvements therein that the Board
deems appropriate. In carrying out its
responsibilities, the Board examines
Academy programs to determine
whether these programs further the
basic missions that are approved by the
Administrator of FEMA, examines the
physical plant of the Academy to
E:\FR\FM\11MYN1.SGM
11MYN1
]]>Agencies
[Federal Register Volume 85, Number 91 (Monday, May 11, 2020)]
[Notices]
[Pages 27756-27757]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09961]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under OMB review, in compliance with the Paperwork
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these
documents, email or call the SAMHSA Reports Clearance Officer at
[email protected] or (240) 276-0361.
Proposed Project: Program Evaluation for Prevention Contract (PEPC)--
Strategic Prevention Framework for Prescription Drugs (SPF-Rx)
Evaluation (OMB No. 0930-0377)--Revision
The Substance Abuse and Mental Health Services Administration's
(SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ)
aims to complete a cross-site evaluation of SAMHSA's Strategic
Prevention Framework for Prescription Drugs (SPF-Rx). SPF-Rx is
designed to address nonmedical use of prescription drugs as well as
opioid overdoses by raising awareness about the dangers of sharing
medications and by working with pharmaceutical and medical communities
on the risks of overprescribing. The SPF-Rx program aims to promote
collaboration between states/tribes and pharmaceutical and medical
communities to understand the risks of overprescribing to youth ages
12-17 and adults 18 years of age and older. The program also aims to
enhance capacity for, and access to, Prescription Drug Monitoring
Program (PDMP) data for prevention purposes. This request for data
collection includes a revision from previously approved OMB
instruments.
The SPF-Rx program's indicators of success are reductions in opioid
overdoses, reductions in prescription drug misuse, and improved use of
PDMP data. Data collected through the tools described in this statement
will be used for the national cross-site evaluation of SAMHSA's SPF-Rx
program. This package covers continued data collection through 2023.
The PEPC team will systematically collect and maintain an Annual
Implementation Instrument (AII) and Grantee and Community Level
Outcomes data modules submitted by SPF-Rx grantees through the online
Data Management System (DMS).
SAMHSA is requesting approval for data collection for the SPF-Rx
cross-site evaluation with the following instruments:
Annual Implementation Instrument (AII)--The AII is a
survey instrument collected yearly to monitor state, tribal entity, and
community-level performance, and to evaluate the effectiveness of the
SPF-Rx program. This tool is completed by grantees and subrecipient
community project directors, and provides process data related to
funding use and effectiveness, organizational capacity, collaboration
with community partners, data infrastructure, planned intervention
targets, intervention implementation, evaluation, contextual factors,
training and technical assistance (T/TA) needs, and sustainability.
Grantee-and Community-Level Outcomes Modules--These
modules collect data on key SPF-Rx program outcomes, including opioid
prescribing patterns and provider use of PDMP. Grantees will provide
outcomes data at the grantee level for their state, tribal area, or
jurisdiction, as well as at the community level for each of their
subrecipient communities.
Grantee-Level Interview--This qualitative interview will
be
[[Page 27757]]
administered at the end of the evaluation to obtain information from
the grantee project directors on their programs, staffing, populations
of focus, infrastructure, capacity, lessons learned, and collaboration.
Annualized Data Collection Burden by Year
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Annual implementation instrument 148 1 148 4 592
Grantee-Level Outcomes Module... 25 1 25 2.5 62.5
Community-Level Outcomes Module. 25 4.92 123 1.25 153.75
Grantee-Level Interview......... 25 1 25 1.5 37.5
-------------------------------------------------------------------------------
FY2021...................... 223 .............. 321 .............. 845.75
Annual Implementation Instrument 148 1 148 4 592
Grantee-Level Outcomes Module... 25 1 25 2.5 62.5
Community-Level Outcomes Module. 25 4.92 123 1.25 154.75
-------------------------------------------------------------------------------
FY2022...................... 198 .............. 296 .............. 808.25
Annual Implementation Instrument 39 1 39 4 156
Grantee-Level Outcomes Module... 7 1 7 2.5 17.5
Community-Level Outcomes Module. 7 4.57 32 1.25 40
-------------------------------------------------------------------------------
FY2023...................... 53 .............. 78 .............. 213.5
----------------------------------------------------------------------------------------------------------------
Written comments and recommendations for the proposed information
collection should be sent within 30 days of publication of this notice
to www.reginfo.gov/public/do/PRAMain. Find this particular information
collection by selecting ``Currently under 30-day Review--Open for
Public Comments'' or by using the search function.
Carlos Graham,
Social Science Analyst.
[FR Doc. 2020-09961 Filed 5-8-20; 8:45 am]
BILLING CODE 4162-20-P
